Heat Biologics, Inc. and Pelican Therapeutics, Inc. Appoint Anthony Tolcher, M.D., FRCPC, FACP to Their Respective Scientific Advisory Boards
March 19, 2018 at 03:15 pm IST
Share
Heat Biologics, Inc. (Heat), along with its subsidiary, Pelican Therapeutics (Pelican) announced the appointment of Anthony Tolcher, M.D., FRCPC, FACP to each of their respective scientific advisory boards. Dr. Tolcher is a medical oncologist who has more than 25 years of early drug development and clinical trial experience and is currently a principal investigator for 20 Phase 1 clinical studies. He is a reviewer for the Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology; and has chaired the Developmental Therapeutics Review Committee for the American Society for Clinical Oncology Annual Scientific Program. Dr. Tolcher has been involved in many of the initial Phase 1 studies of new agents that subsequently were FDA approved for the treatment of cancer.
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.